A third study evaluated GVAX, an allogeneic pancreatic cancer vaccine in combination with either nivolumab (PD-1 inhibitor) or both nivolumab and urelumab (an agonist of the T-cell costimulatory molecule CD137). Here, TNFRSF9 is linked to pancreatic neoplasm.